|
|
|
The expression of an intestinal epithelial cell receptor is silenced in most human colorectal cancers that progress from benign to malignant, according to a Biology Letter in the 23 June 2005 issue of Nature (Vol. 435, No. 7045, pp. 1126-1130). In addition, Hans Clevers and colleagues report that loss of expression of this receptor, EphB2, accelerates the progression of colorectal cancer in mice.
This study contradicts previous work suggesting that EphB2 would be a good target in cancer therapy because of its overall upregulation in colorectal cancers compared with normal intestinal tissue. The authors note that this discrepancy underscores the need for careful study of potential drug targets. CONTACT Hans Clevers (Hubrecht Laboratory, Utrecht, The Netherlands)
E-mail: clevers@niob.knaw.nl (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|